Skip to main content

pegvaliase

Generic: pegvaliase·Brand: Palynziq

pegvaliase: 7 clinical trials tracked.

pegvaliase evidence translation

What we can confirm

7 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about pegvaliase, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 1 study sponsors
Clinical Trials (7)

A Phase 4 Study of Immune Modulation During Palynziq® Treatment in Adults With Phenylketonuria (PKU)

NCT07477691·Phase 4·BMRN
Recruiting

Primary endpoint: Change in blood Phe levels from baseline to Week 25 and Week 49

Interventionalopen12 targetStarted 2026-05Completion 2027-0912 sites · United StatesBioMarin Pharmaceutical

A Multi-Center, Prospective, Longitudinal, Study Evaluating Immunologic, Inflammatory, and Laboratory Parameters Associated With Long-Term Palynziq® (Pegvaliase) Treatment in Subjects With Phenylketonuria (PKU) in the United States

Recruiting

Primary endpoint: To evaluate immunologic and inflammatory responses associated with occurrences of

Observational200 targetStarted 2024-01Completion 2033-1111 sites · United StatesBioMarin Pharmaceutical

A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and Breastfeeding

Recruiting

Primary endpoint: Pregnancy outcome and infant development for women who have been treated with Palynziq (pegvaliase) within 2 weeks of their last menstrual period

Observational50 targetStarted 2022-11Completion 2032-104 sites · Canada, Germany, Italy, United StatesBioMarin Pharmaceutical

A Phase 3 Multi-Center Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase in Adolescent Subjects (Ages 12-17) With Phenylketonuria- Open-Label Randomized Two-Arm (Active vs Diet-Only Control)

NCT05270837·Phase 3·BMRN
Active, not recruiting

Primary endpoint: Change From Baseline in Blood Phe Concentration Following 72 Weeks (Average of the Week 69 and Week 73) on Study.

InterventionalRandomizedopen55 enrolledStarted 2022-06Completion 2027-1016 sites · Germany, United StatesBioMarin Pharmaceutical

A Multi-Center, Observational Study to Evaluate the Long-Term Safety of Subcutaneous Injections of Palynziq® (Pegvaliase) in Subjects With Phenylketonuria

Recruiting

Primary endpoint: To quantify and characterize the risk of protocol-defined safety events in incident-users receiving pegvaliase for the treatment of PKU in a real¬ world setting.

Observational450 targetStarted 2022-06Completion 2033-1126 sites · Germany, Italy, United StatesBioMarin Pharmaceutical

A Preliminary Study of the Neurological and Neuropsychological Effects of Palynziq-Related Changes in Phenylalanine in Individuals With Phenylketonuria (PKU)

Completed

Primary endpoint: Neurologic Integrity

Observational6 enrolledStarted 2022-05Completion 2025-072 sites · United StatesUniversity of Missouri-Columbia

Palynziq and PKU: Treatment Impacts on Diet Quality, Neurological Health, Nutritional Status, and the Metabolome

Recruiting

Primary endpoint: Intra-subject Change in Intact Protein Intake

Observational45 targetStarted 2019-10Completion 2028-122 sites · United StatesEmory University